Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
NEW YORK (Reuters Health) – An updated review of medications available for treating type 2 diabetes concludes that metformin continues to have the best benefit-to-harm profile, according to…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses the diagnosis of prostate cancer and what a man needs to know. The three…
NEW YORK (Reuters Health) – A low-dose regimen of peginterferon, without ribavirin, produces a sustained virologic response in up to 40% of patients with chronic hepatitis C and…
NEW YORK (Reuters Health) – Pain associated with diabetic neuropathy is improved to a similar degree with daily amitriptyline or duloxetine, according to the results of a cross-over…
NEW YORK (Reuters Health) – A new study provides more evidence that influenza vaccine reduces major cardiovascular events in patients hospitalized for acute coronary syndrome (ACS). In the…
NEW YORK (Reuters Health) – Ribavirin added to pegylated interferon more than doubles the sustained viral response rate in children with chronic hepatitis C, a multicenter team reports…
NEW YORK (Reuters Health) – For women with low-risk gestational trophoblastic neoplasia, dactinomycin given every 2 weeks had a higher complete response rate than weekly methotrexate in a…
NEW YORK (Reuters Health) – Compared to conventional white light bronchoscopy, autofluorescence bronchoscopy is more sensitive in detecting lung cancer and preneoplastic lesions, according to a meta-analysis conducted…
NEW YORK (Reuters Health) – HCV genotype 4, previously limited to Egypt and parts of Africa, has now spread to southern Europe and other parts of world, an…
Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 2. San Antonio Breast Cancer Symposium attendees this week considered evidence that bevacizumab…
